arrow
B

Bryan T. Mayer

Fred Hutchinson Cancer Center
H指数:23
被引数:2,027

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials

抗体介导预防试验中,使用广谱中和抗体VRC01进行预防性治疗会在感染后选择逃逸突变体

2026-09-280
OA
Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial

有或没有HIV-1的人的双特异性10E8.4/iMab广泛中和抗体: 部分随机的1期试验

2026-07-070
OAAI
Addition of blood-stage antibody enhances anti-sporozoite antibody protection in a humanized mouse model of Plasmodium falciparum infection

在恶性疟原虫感染的人源化小鼠模型中,血阶段抗体增强抗子孢子抗体的保护作用

2026-06-220
OAAI
Clinical trial simulation of antiviral drugs

抗病毒药物的临床试验模拟

2026-05-191
PRE
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials

在抗体介导的预防试验中,广泛中和抗体VRC01对HIV突破性病毒人群的影响

2026-04-030
OAAI
Hydrogel formulations for sustained-release of broadly neutralizing antibodies

长效广谱中和抗体的水凝胶制剂

2025-10-310
PRE
Bayesian estimation of HIV acquisition dates for prevention trials

贝叶斯方法估计HIV感染日期用于预防试验

MBIO
IF4.7
2025-09-010
OA
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV

一项全面的工程策略提高了针对HIV的近全中和抗体的效力和可制造性。

2025-05-140
OA
A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions

一种新型的HIV三重广谱中和抗体(bNAb)组合为基础的被动免疫方法,应用于婴儿恒河猴,能够实现持久的保护性血浆中和水平,并介导抗病毒效应功能。

2024-11-111
OA
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
2024-04-273
OAAI
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials ( vol 14 , 8299 , 2023)
2024-03-220
OAAI
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
2023-12-144
OAAI
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
2022-08-2254
OAAI
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
2022-05-1270
OAAI
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
2021-10-0750
OAAI